{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:32:29Z","timestamp":1772767949264,"version":"3.50.1"},"reference-count":13,"publisher":"BMJ","issue":"3","funder":[{"name":"UBC Steven Diamond Professorship in Addiction Care Innovation","award":["Dr. Nolan is supported by UBC's Steven Diamond Pro"],"award-info":[{"award-number":["Dr. Nolan is supported by UBC's Steven Diamond Pro"]}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","award":["Dr. Nolan is supported by a Michael Smith Foundati"],"award-info":[{"award-number":["Dr. Nolan is supported by a Michael Smith Foundati"]}],"id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,3,10]]},"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:p>In the wake of North America\u2019s opioid crisis, access to evidence-based treatment for opioid use disorder (OUD) is of critical importance. While buprenorphine\/naloxone and methadone are currently indicated as first-line medications for the treatment of OUD, there are a proportion of individuals who do not benefit from these therapies. Recent Canadian guidelines suggest the use of alternate therapies, including slow-release oral morphine or injectable opioid agonist therapy (iOAT) for individuals unsuccessful with either methadone or buprenorphine\/naloxone. While the guidelines highlight the need to intensify OUD treatment as disease severity increases, equally important is the consideration for deintensification of treatment (eg, from iOAT to an oral opioid agonist treatment (OAT) option) following successful stabilisation. Literature addressing how best to accomplish this, however, is currently lacking. Accordingly, the case presented here describes a patient that successfully transitions from iOAT to oral buprenorphine\/naloxone using a novel induction approach termed microdosing.<\/jats:p>","DOI":"10.1136\/bcr-2019-233715","type":"journal-article","created":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T16:15:15Z","timestamp":1585152915000},"page":"e233715","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Transitioning a patient from injectable opioid agonist therapy to sublingual buprenorphine\/naloxone for the treatment of opioid use disorder using a microdosing approach"],"prefix":"10.1136","volume":"13","author":[{"given":"Mackenzie Duncan Gregory","family":"Caulfield","sequence":"first","affiliation":[{"name":"Department of Family Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupinder","family":"Brar","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christy","family":"Sutherland","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seonaid","family":"Nolan","sequence":"additional","affiliation":[{"name":"Department of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"BC Centre on Substance Use, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,3,25]]},"reference":[{"key":"2025082804044684000_13.3.e233715.1","unstructured":"Center for Disease Control and Prevention . Opioid Overdose: Understanding the Epidemic [internet]. US department of Health and Human Services, 2018. Available: https:\/\/www.cdc.gov\/drugoverdose\/epidemic\/index.html [Accessed 13 Jan 2019]."},{"key":"2025082804044684000_13.3.e233715.2","first-page":"1419","article-title":"And Opioid-Involved overdose deaths \u2014 United States, 2013\u20132017","volume":"67","author":"Scholl","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025082804044684000_13.3.e233715.3","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2017.15971","article-title":"Underlying factors in drug overdose deaths","volume":"318","author":"Dowell","year":"2017","journal-title":"JAMA"},{"key":"2025082804044684000_13.3.e233715.4","unstructured":"Public Health Agency of Canada . National Report: Apparent Opioid-Related deaths in Canada [internet]. Government of Canada, 2018. Available: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy- living\/national-report-apparent-opioid-related-deaths-released-march-2018.html [Accessed 13 Jan 2019]."},{"key":"2025082804044684000_13.3.e233715.5","doi-asserted-by":"crossref","first-page":"224","DOI":"10.24095\/hpcdp.38.6.02","article-title":"Evidence synthesis: the opioid crisis in Canada: a national perspective","volume":"38","author":"Belkaz","year":"2018","journal-title":"Health Promot Chronic Dis Prev Can"},{"key":"2025082804044684000_13.3.e233715.6","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40429-018-0231-x","article-title":"The threat of an international opioid crisis","volume":"5","author":"Nolan","year":"2018","journal-title":"Curr Addict Rep"},{"key":"2025082804044684000_13.3.e233715.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00161-6"},{"key":"2025082804044684000_13.3.e233715.8","unstructured":"British Columbia Centre on Substance Use and B.C. Ministry of Health . A guideline for the clinical management of opioid use disorder. BCCSU 2017:33\u20134."},{"key":"2025082804044684000_13.3.e233715.9","doi-asserted-by":"crossref","unstructured":"Davis M , Glare P . Opioids in cancer pain. 2nd edn. Oxford, UK: Oxford University Press, 2009: 211\u20132.","DOI":"10.1093\/med\/9780199236640.003.0013"},{"key":"2025082804044684000_13.3.e233715.10","doi-asserted-by":"publisher","DOI":"10.2174\/1570159043359477"},{"key":"2025082804044684000_13.3.e233715.11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2147\/SAR.S109919","article-title":"Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method","volume":"7","author":"H\u00e4mmig","year":"2016","journal-title":"Subst Abuse Rehabil"},{"key":"2025082804044684000_13.3.e233715.12","first-page":"129","article-title":"Einleitung einer Substitutionsbehandlung mit Buprenorphin unter vor\u00fcbergehender \u00dcberlappung mit Heroinkonsum: ein neuer Ansatz (\u201cBerner Methode\u201d)","volume":"11","author":"H\u00e4mmig","year":"2010","journal-title":"[Induction of a buprenorphine substitution treatment with temporary overlap of heroin use: a new approach (\u201cBernese Method\u201d)] Suchttherapie"},{"key":"2025082804044684000_13.3.e233715.13","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/ajad.12869","article-title":"Rapid micro-induction of buprenorphine\/naloxone for opioid use disorder in an inpatient setting: a case series","volume":"28","author":"Klaire","year":"2019","journal-title":"Am J Addict"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-233715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:04:55Z","timestamp":1756379095000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-233715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":13,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3,25]]},"published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1136\/bcr-2019-233715"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-233715","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3]]}}}